Frequency of Conduction Abnormalities After Transcatheter Aortic Valve Implantation With the Medtronic-CoreValve and the Effect on Left Ventricular Ejection Fraction - 06/08/11
, Bas M. van Dalen, MD, PhD, Nicolas M. Van Mieghem, MD, Juan-Luis Gutierrez-Chico, MD, PhD, Rutger-Jan Nuis, MS, Floris Kauer, MD, Carl Schultz, MD, PhD, Patrick W. Serruys, MD, PhD, Peter P.T. de Jaegere, MD, PhD, Marcel L. Geleijnse, MD, PhDRésumé |
New conduction abnormalities occur frequently after transcatheter aortic valve implantation (TAVI). The relation between new conduction disorders and left ventricular (LV) systolic function after TAVI is unknown. The purpose of the present prospective, single-center study was to investigate the effect of TAVI on LV systolic function in relation to TAVI-induced conduction abnormalities. A total of 27 patients had undergone electrocardiography and transthoracic echocardiography the day before and 6 days after TAVI with the Medtronic-CoreValve system. The LV ejection fraction (EF) was calculated using the biplane Simpson method. The systolic mitral annular velocities and longitudinal strain were measured using speckle tracking echocardiography. After TAVI, 18 patients (67%) had new conduction abnormalities; 4 (15%) had a new paced rhythm and 14 patients (52%) had new left bundle branch block. In the patients with new conduction abnormalities, the EF decreased from 47 ± 12% to 44 ± 10%. In contrast, in those without new conduction abnormalities, the EF increased from 49 ± 12% to 54% ± 12%. The change in EF was significantly different among those with and without new conduction abnormalities (p <0.05). In patients without new conduction abnormalities, an improvement was found in the systolic mitral annular velocities and longitudinal strain (p <0.05). In contrast, in patients with new conduction abnormalities, the changes were not significant. In conclusion, the induction of new conduction abnormalities after TAVI with the Medtronic-CoreValve was associated with a lack of improvement in LV systolic function.
Le texte complet de cet article est disponible en PDF.Plan
| Dr Tzikas was supported by an unrestricted research grant from the European Association of Percutaneous Cardiovascular Interventions, Sophia Antipolis, France (EAPCI Interventional Cardiology Research Grant 2009). |
Vol 107 - N° 2
P. 285-289 - janvier 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
